2017

BORTEZOMIB-TEVA

The brochure contains instructions on preparation, dosing and methods of administration of the medicinal product (intravenous or subcutaneous), storage conditions for the solution and the procedure for reporting adverse events. Intended for healthcare professionals. generated automatically

LUCENTIS

Guide for physicians on the intravitreal use of ranibizumab: indications, injection technique, and prevention and management of the main injection risks (endophthalmitis, cataract, increased intraocular pressure, retinal detachment). generated automatically

Aranesp

Myozyme

NovoPen Echo

Multaq®

Komboglyze

Esbriet

Information material for healthcare professionals on the safe use of a medicinal product for the treatment of idiopathic pulmonary fibrosis. Contains warnings about the risks of liver injury and photosensitivity, monitoring requirements and recommendations on informing patients. compiled automatically

Zelboraf

Informational letter to healthcare professionals on precautions when using Zelboraf (vemurafenib): cases of Dupuytren’s contracture and plantar fascial fibromatosis have been reported. Contains recommendations on dose adjustment, temporary interruption or discontinuation of treatment, and reporting of adverse reactions. generated automatically

Cotellic (cobimetinib)

Informational letter for healthcare professionals on additional cases of severe bleeding, including intracranial and gastrointestinal, with the use of Cotellic, with recommendations on dose modification and an update of the instructions. generated automatically